Page 33 - Read Online

Page 12 of 12 Ossoliński et al. J Cancer Metastasis Treat 2019;5:1 I http://dx.doi.org/10.20517/2394-4722.2018.63

cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.
33. Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, et al. Cholesterol metabolism and prostate cancer lethality. Cancer Res
2016;76:4785-90.
34. Allott EH, Howard LE, Cooperberg MR, Kane CJ, Aronson WJ, et al. Serum lipid profile and risk of prostate cancer recurrence: results
from the SEARCH database. Cancer Epidemiol Biomarkers Prev 2014;23:2349-56.
35. Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer
in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2009;18:2807-13.
36. Mondul AM, Clipp SL, Helzlsouer KJ, Platz EA. Association between plasma total cholesterol concentration and incident prostate cancer in
the CLUE II cohort. Cancer Causes Control 2009;21:61-8.
37. Kok DE, van Roermund JG, Aben KK, den Heijer M, Swinkels DW, et al. Blood lipid levels and prostate cancer risk; a cohort study.
Prostate Cancer Prostatic Dis 2011;14:340-5.
38. Wuermli L, Joerger M, Henz S, Schmid HP, Riesen WF, et al. Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate
Cancer Prostatic Dis 2005;8:316-20.
39. Platz EA, Clinton SK, Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int J Cancer
2008;123:1693-8.
40. Eberlin LS, Dill AL, Costa AB, Ifa DR, Cheng L, et al. Cholesterol sulfate imaging in human prostate cancer tissue by desorption
electrospray ionization mass spectrometry. Anal Chem 2010;82:3430-4.
41. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006;9:230-4.
42. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 2010;6:551-62.
43. Giskeødegård GF, Hansen AF, Bertilsson H, Gonzalez SV, Kristiansen KA, et al. Metabolic markers in blood can separate prostate cancer
from benign prostatic hyperplasia. Br J Cancer 2015;113:1712-9.
44. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of
androgen deprivation therapy for prostate cancer. Clin Cancer Res 2012;18:3677-85.
45. Fu YQ, Zheng JS, Yang B, Li D. Effect of individual omega-3 fatty acids on the risk of prostate cancer: a systematic review and dose-
response meta-analysis of prospective cohort studies. J Epidemiol 2015;25:261-74.
46. Murphy AB, Nyame Y, Martin IK, Catalona WJ, Hollowell CM, et al. Vitamin D deficiency predicts prostate biopsy outcomes. Clin Cancer
Res 2014;20:2289-99.
47. Gilbert R, Metcalfe C, Fraser WD, Donovan J, Hamdy F, et al. Associations of circulating 25-hydroxyvitamin D with prostate cancer
diagnosis, stage and grade. Int J Cancer 2011;131:1187-96.
48. Ben-Eltriki M, Deb S, Guns ES. Calcitriol in combination therapy for prostate cancer: pharmacokinetic and pharmacodynamic interactions.
J Cancer 2016;7:391-407.
49. Marshall DT, Savage SJ, Garrett-Mayer E, Keane TE, Hollis BW, et al. Vitamin D3 supplementation at 4000 international units per day for
one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin
Endocrinol Metab 2012;97:2315-24.
50. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel
compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J Clin Oncol
2007;25:669-74.
51. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, et al. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of
anti-inflammatory activity. J Bone Miner Res 2007;22:V74-80.
52. Moreno J, Krishnan AV, Feldman D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J
Steroid Biochem Mol Biol 2005;97:31-6.
53. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, et al. Vitamin C exhibits pro-oxidant properties. Nature 1998;392:559.
54. Davies O, Mendes P, Smallbone K, Malys N. Characterisation of multiple substrate-specific (d)ITP/(d)XTPase and modelling of deaminated
purine nucleotide metabolism. BMB Rep 2012;45:259-64.
55. Ji D, Stepchenkova EI, Cui J, Menezes MR, Pavlov YI, et al. Measuring deaminated nucleotide surveillance enzyme ITPA activity with an
ATP-releasing nucleotide chimera. Nucleic Acids Res 2017;45:11515-24.